However, several clinical trials have been carried out in order to assess the possible efficacy of recombinant IGF-I in other pathologies such as diabetes I and II (20), ALS (amyotrophic lateral sclerosis), Alzheimer, anorexia nervosa or osteoporosis. The gene discussed is IGF1; the disease is anorexia nervosa.